Homology Medicines Inc (NASDAQ:FIXX) is Vivo Capital LLC’s 9th Largest Position

Vivo Capital LLC grew its position in Homology Medicines Inc (NASDAQ:FIXX) by 21.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,409,742 shares of the company’s stock after purchasing an additional 250,000 shares during the quarter. Homology Medicines comprises approximately 3.7% of Vivo Capital LLC’s investment portfolio, making the stock its 9th biggest position. Vivo Capital LLC owned about 3.76% of Homology Medicines worth $28,759,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. FMR LLC grew its stake in shares of Homology Medicines by 12.9% in the 2nd quarter. FMR LLC now owns 3,359,715 shares of the company’s stock worth $67,192,000 after buying an additional 384,818 shares in the last quarter. BlackRock Inc. purchased a new position in shares of Homology Medicines in the 2nd quarter worth $10,831,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Homology Medicines in the 2nd quarter worth about $998,000. Bank of New York Mellon Corp bought a new stake in shares of Homology Medicines in the 2nd quarter worth about $558,000. Finally, Millennium Management LLC bought a new stake in shares of Homology Medicines in the 1st quarter worth about $1,700,000. 55.01% of the stock is currently owned by institutional investors.

Several equities research analysts have recently issued reports on FIXX shares. Zacks Investment Research upgraded shares of Homology Medicines from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a report on Thursday, August 16th. B. Riley started coverage on shares of Homology Medicines in a report on Friday, September 7th. They issued a “neutral” rating and a $18.50 target price for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $25.90.

Shares of Homology Medicines stock opened at $20.02 on Friday. Homology Medicines Inc has a 52-week low of $15.07 and a 52-week high of $24.40.

Homology Medicines (NASDAQ:FIXX) last released its earnings results on Monday, August 13th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.02). The business had revenue of $0.93 million for the quarter. sell-side analysts forecast that Homology Medicines Inc will post -1.26 EPS for the current year.

Homology Medicines Profile

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Recommended Story: How Important is Technical Analysis of Stocks

Institutional Ownership by Quarter for Homology Medicines (NASDAQ:FIXX)

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply